Qiteng Xiaozhuo granules medicated serum inhibits excessive proliferation and promotes apoptosis of human glomerular mesangial cells by targeting fat mass and obesity associated proteins.

OBJECTIVE: To explore whether fat mass and obesity associated proteins (FTO) is an important target of Qiteng Xiaozhuo granules (QTXZG,) medicated serum in regulating proliferation and apoptosis of glomerular mesangial cells. METHODS: Medicated serum was obtained from Sprague-Dawley (SD) rats administered intragastrically with QTXZG decoction. The optimal concentration and intervention time of medicated serum were selected with the cell counting kit 8 assay. Cell proliferation was assessed by 5-ethynyl-2'-deoxyuridine (EdU) and cell apoptosis was investigated using flow cytometry. The expression of FTO, Proliferating cell nuclear antigen, Cyclin D1, B-cell lymphoma 2 (Bcl2) and BCL2 assaciated X was detected by Western blot and Real-time quantitative polymerase chain reaction, respectively. Quantification of the m6A RNA methylation was utilized to determine the total level of m6A methylation modification. RESULTS: EdU and flow cytometry assays revealed that QTXZG medicated serum can remarkably inhibit proliferation and promote apoptosis of lipopolysaccharide (LPS)-induced human glomerular mesangial cells (HGMCs). The FTO overexpression plasmid could inhibit proliferation and promote apoptosis of LPS-induced HGMCs. The FTO inhibitor (FB23-2) can significantly attenuate the effect of QTZXG medicated serum on inhibiting excessive proliferation and promoting apoptosis. QTXZG medicated serum can significantly increase FTO expression and decrease the level of m6A methylation modification. CONCLUSIONS: FTO is a key target for QTXZG medicated serum in inhibiting excessive proliferation and promoting apoptosis of human glomerular mesangial cells.

Relationship of OPRM1 118A/G gene polymorphism and oxycodone analygesic dose in paitents with cancer pain / 中华医学遗传学杂志

OBJECTIVE@#To investigate the relationship between OPRM1 118A/G gene polymorphism and oxycodone analgesic dose in patients with cancer pain.@*METHODS@#DNA sequencing was used to detect the genotypies of OPRM1 118 A/G site in 203 patients with moderate and severe cancer pain, and to compare the relationship between the pain degree and the dose of oxycodone at 3 and 30 days after treatment in patients with different genotypes.@*RESULTS@#The fequencies of AA, AG and GG genotypes at the OPRM1 118 A/G site were 34.78%, 52.70%, and 12.52%, respectively. The dosage of oxycodone in GG genotype was significantly higher than that in AA genotype and AG genotype (15.44±10.19 vs. 10.25±4.53, 10.49±5.26; 89.15±27.69 vs. 43.59±12.19, 48.27±18.79) on the 3 and 30 day after treatment, difference was statistically significant (P< 0.05).@*CONCLUSION@#For cancer pain patients with GG genotype of OPRM1 118A/G site, if they need to achieve the same analgesic effect as patients with AA and AG genotype, the dose of oxycodone should be increased.

Influence of circadian genes hClock and hBmal1 on the chemosensitivity of gastric cancer / 中国肿瘤临床

Objective:To study the influernce of circadian genes hClock and hBmal1 on the chemosensitivity of SGC-7901 cells. Methods: SGC-7901 cells were cultivated under continuous darkness in vitro.The expression levels of the two main circadian genes hClock and hBmal1 at the different time were determined by real-time polymerase chain reaction(PCR). Docetaxel was administered at the peak and nadir time point respectively. The inhibition of SGC-7901 cell proliferation was measured using a CCK-8 kit. Result:The expression of circadian genes hClock and hBmal1 varied at different times, as shown by real-time PCR. The expression of circadian genes hClock and hBmal1 showed Phase oseillation. The maximum expression of hClock and hBmal1 mRNA was at 20:00. whereas their minimum expression was at 08:00. The inhibition ratio of docetaxel to SGC-7901 cells at the maximum expression of hClock and hBmal1 genes was lower than that at the minimum expression. Conclusion:Circadian Genes hClock and hBmal1 can reduce the drug sensitivity of SGC-7901 cell line to docetaxel in vitro.